Fenwick represented Stoke Therapeutics, Inc., a biotechnology firm developing therapies for genetic diseases, in its strategic collaboration and licensing agreement with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD). Stoke and Acadia will work to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.
Under the terms of the agreement, Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales. More information about the collaboration can be obtained from the announcement.
The Fenwick transaction team included life sciences partner Stefano Quintini and counsel Amy Klann; and tax partner Will Skinner.